Jeremy A. Ross

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Matthew S. Davids, Andrew W. Roberts, John F. Seymour et al. · Journal of Clinical Oncology · 2017 · 737 citations · Full text

Immunology, Pathology, Pharmacotherapy +17

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

Shaji Kumar, Jonathan L. Kaufman, Cristina Gasparetto et al. · Blood · 2017 · 517 citations · Full text

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

Shaji Kumar, Simon J. Harrison, Michèle Cavo et al. · The Lancet Oncology · 2020 · 390 citations

Hematological Malignancy, Oncology, Hematology +7

Serine proteases and their homologs in the Drosophila melanogaster genome: an initial analysis of sequence conservation and phylogenetic relationships

Jeremy A. Ross, Haobo Jiang, Michael R. Kanost et al. · Gene · 2003 · 317 citations

Comparative Genomics, Genetics, Drosophila Melanogaster Genome +13

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM

Philippe Moreau, Asher Chanan‐Khan, Andrew W. Roberts et al. · Blood · 2017 · 271 citations · Full text